TICKERNERD
Menu
INCYINCYHealthcare · Biotechnology

INCY Stock Forecast: Incyte Corp. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$121
−1.47% on the day

The 28 Wall Street analysts covering Incyte Corp. hold a median 12-month price target of $130 — +7.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 90 of 100 as at 12 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$24.6B
Ticker Nerd rank
90 / 100
Median analyst target
$130
Analysts covering
28
Revenue$1.7B+37.7% y/y
Operating income$700.4M
Net income$585.6M
Free cash flow$495.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.1%
1M
+0.3%
YTD
+23.0%
1Y
+41.0%
From 52W high
−6.5%
From 52W low
+48.8%
$82
$130
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

INCY stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Incyte Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
90 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
99
Value
99
Quality
97
Growth
85
Momentum
85
Issuance
72
Revisions
46
Accruals
46
Size
9

Volatility (99): The share price has been relatively steady.

Accruals (46): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (9): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

INCY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on INCY, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$80$100$120$140$160Oct 25Jan 26Apr 26Jul 26INCYHigh $155Median $130Low $86

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says28 analysts
12 Buy15 Hold1 Sell
Low $86Median $130High $155

The green dot is the last close — the median target sits +7.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
20 Aug 2026Canaccord GenuityInitiatesBuy$152
20 Aug 2026HC Wainwright & Co.ReiteratesBuy$150
17 Aug 2026Piper SandlerMaintainsOverweight$110 → $130
4 Aug 2026MizuhoMaintainsOutperform$121 → $137
4 Aug 2026MizuhoMaintainsOutperform—
3 Aug 2026HC Wainwright & Co.ReiteratesBuy$150
3 Aug 2026HC Wainwright & Co.ReiteratesBuy—
3 Aug 2026Leerink PartnersMaintainsOutperform$131 → $155
3 Aug 2026Leerink PartnersMaintainsOutperform—
29 July 2026BarclaysMaintainsOverweight—
29 July 2026BarclaysMaintainsOverweight$134 → $139
29 July 2026BMO CapitalMaintainsMarket Perform—
29 July 2026BMO CapitalMaintainsMarket Perform$112 → $130
29 July 2026GuggenheimMaintainsBuy—
29 July 2026HC Wainwright & Co.MaintainsBuy$140 → $150
29 July 2026HC Wainwright & Co.MaintainsBuy—
29 July 2026RBC CapitalMaintainsSector Perform—
29 July 2026RBC CapitalMaintainsSector Perform$99 → $109
23 July 2026JP MorganMaintainsNeutral—
23 July 2026JP MorganMaintainsNeutral$105 → $110

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. INCY appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

INCY vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Incyte Corp. returned +41.0% against +17.5% for the S&P 500, dividends included.

INCY vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140150Oct 25Jan 26Apr 26Jul 26INCYS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

INCY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−54.9%
Analysts raising
0
Analysts cutting
11
Fundamentals

Incyte Corp. (INCY) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
15.5×

Cheaper than 45% of US stocks

Price / sales
4.2×

Cheaper than 29% of US stocks

Price / book
3.8×

Cheaper than 26% of US stocks

EV / EBITDA
10.4×

Cheaper than 37% of US stocks

Growth & margins
Revenue growth (YoY)
37.7%

Higher than 82% of US stocks

Earnings growth (YoY)
44.6%

Higher than 73% of US stocks

Gross margin
93.7%

Higher than 98% of US stocks

Operating margin
41.9%

Higher than 93% of US stocks

Net margin
27.7%

Higher than 87% of US stocks

Returns & dividend
Return on equity
30.7%

Higher than 88% of US stocks

Return on assets
16.8%

Higher than 98% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Incyte Corp. (INCY) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Incyte Corp. has a market value of $24.6B and an enterprise value of $20.1B.

  • Revenue in the twelve months to 30 June 2026: $5.8B. The latest quarter grew 37.7% year on year.

  • Net income over the same four quarters: $1.6B, a 27.7% net margin.

  • Diluted earnings per share, trailing twelve months: $7.85.

  • Free cash flow in the twelve months to 30 June 2026: $1.9B, after $59.2M of capital spending.

  • Shares outstanding: 201.0M.

  • Trailing P/E: 15.5×; forward P/E: 13.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Incyte Corp. employs 2,844 people — $2.0M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

INCY vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
INCYIncyte Corp.$24.6B
90
INSMInsmed, Inc.$28.3B
85
ROIVRoivant Sciences Ltd.$29.2B
38
ALNYAlnylam Pharmaceuticals, Inc.$32.9B
50
RPRXRoyalty Pharma plc$33.8B
87
JAZZJazz Pharmaceuticals Plc$15.4B
99
EXELExelixis, Inc.$14.6B
98

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Incyte Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest INCY news & analysis

Profitable Biotech Incyte Forms Handle As Institutional Buyers Load Up On Stock

Investors Business Daily · 11 Sept 2026positive

Incyte is reportedly forming a technical handle pattern as institutional investors increase their positions, with the stock trading just below a buy zone according to Investors Business Daily.

Why it matters — The item signals that large institutional investors are accumulating INCY shares, a development that can influence the stock's direction and is relevant to those tracking the company.

Incyte Corporation (INCY) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Seeking Alpha · 10 Sept 2026neutral

Incyte Corporation presented at the 12th Annual Cantor Fitzgerald Global Healthcare Conference, with a transcript of the presentation published via Seeking Alpha. The item reports on the company's conference appearance.

Why it matters — An INCY watcher would care because the conference presentation provides insight into how the company communicates its business to the investment community.

Incyte Corporation (INCY) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Seeking Alpha · 9 Sept 2026neutral

Incyte Corporation presented at the Wells Fargo 21st Annual Healthcare Conference, with a transcript of the presentation published on Seeking Alpha. The presentation covered Incyte's corporate update at the investor event.

Why it matters — The presentation gives INCY investors a direct view of the company's latest strategic positioning and disclosures shared with the financial community.

Should First Trust Large Cap Growth AlphaDEX ETF (FTC) Be on Your Investing Radar?

Zacks Investment Research · 9 Sept 2026neutral

Zacks Investment Research published a piece examining whether the First Trust Large Cap Growth AlphaDEX ETF (FTC) should be on investors' radar. The article notes the fund was launched on May 7, 2007, and is a passively managed exchange-traded fund providing broad exposure to the Large Cap Growth segment of the US equity market.

Why it matters — For an INCY watcher, the piece relates to a passively managed large-cap growth ETF that may hold stocks like INCY within its broad US equity exposure.

Incyte Corporation: Why Jakafi Is No Longer The Real Story Here

Seeking Alpha · 2 Sept 2026positive

Incyte is transitioning from a Jakafi-centric model to a diversified, multi-franchise biotech, with 2Q26 results showing 17% underlying net sales growth and broad-based portfolio expansion. Its late-stage pipeline maturity and upcoming 2H26 clinical readouts across dermatology, hematology, and oncology are seen as key to validating its multi-engine growth thesis.

Why it matters — Incyte watchers would care because upcoming second-half 2026 clinical readouts and the company's shift to a diversified pipeline will determine whether its multi-franchise growth strategy is validated beyond Jakafi.

FAQ

Frequently asked questions about INCY stock

What is the INCY stock price forecast for 2026-2027?

The 28 Wall Street analysts covering Incyte Corp. have a median 12-month price target of $130, with estimates ranging from $86 to $155. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is INCY stock a buy right now?

Of the 28 analysts covering Incyte Corp., 12 rate it a Buy, 15 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Incyte Corp. 90 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank INCY?

As at 12 Sept 2026, Incyte Corp. ranks 90 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (99 of 100).

Will INCY stock go up?

No one can know that. What the data says: the median 12-month target from 28 analysts implies +7.0% from the last close, and Ticker Nerd's factor model ranks Incyte Corp. 90 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the INCY stock forecast for 2030?

No analyst covering Incyte Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INCY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $86 to $155 over the next 12 months.

How has INCY stock performed over the past year?

Incyte Corp. returned +41.0% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Incyte Corp. do?

Incyte Corp. is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics.

What is the latest news on INCY?

The most recent item we track (Investors Business Daily, 11 Sept 2026): "Profitable Biotech Incyte Forms Handle As Institutional Buyers Load Up On Stock". Incyte is reportedly forming a technical handle pattern as institutional investors increase their positions, with the stock trading just below a buy zone according to Investors Business Daily.

Company

About Incyte Corp.

Incyte Corp. is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. The company’s current portfolio centers on hematology, oncology, and inflammation and autoimmunity, with products and programs aimed at treating cancers, blood disorders, and immune-mediated conditions. Incyte Corp. develops both small-molecule medicines and biologics, and its marketed therapies support patients with a range of specialty disease areas, including dermatology and rare hematologic disorders. The company also maintains a pipeline of clinical-stage candidates across its core therapeutic franchises, reflecting its role as a research-driven developer of targeted treatments. Headquartered in Wilmington, Delaware, Incyte Corp. serves healthcare markets in the United States and internationally through its commercial and development activities.

CEO Mr. William J. Meury · 2,844 employees · United States · https://www.incyte.com